Solid Tumors Clinical Trial
Official title:
International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study
Verified date | September 2017 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Status | Completed |
Enrollment | 37 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria : - Cancer patients greater than 18 years of age who have completed all assessments required to meet the primary objectives of a parental phase 1, 2 or 3 clinical study of iniparib as monotherapy or in a combination regimen. - Previously received and are continuing to derive clinical benefit from iniparib, as monotherapy or in combination with chemotherapy, as determined by the treating physician. - Ongoing treatment with iniparib at time of parental study completion/closure and meet criteria to initiate a subsequent cycle of therapy, as described in the parental study protocol. - On a stable parental study regimen (at least one cycle for the regimen at the dose/schedule that is to be given in the Treatment Extension study must have been given prior to the patient's discontinuation from the parental study). Signed written informed consent. Exclusion criteria: - Patient has not previously participated in any clinical trial of iniparib. - Patient has evidence of progressive disease while receiving iniparib. - Patient has another concurrent invasive malignancy (aside from the malignancy for which the patient has received therapy for on the parental protocol). - Patient has a major medical or co-morbid condition(s) that the investigator believes might compromise safe participation in the study (such as uncontrolled lung, kidney, or liver problems; uncontrolled infection; a history of congestive heart failure; or an electrocardiogram suggesting significant problems with the heart). - Patient has not recovered to baseline or less than Grade 1 from non-hematologic adverse events related to any anticancer therapy received prior to signing informed consent on the Treatment Extension study, with the exception of hair loss. - Patient is receiving concurrent treatment with other investigational agents not allowed as part of the combination regimen in the parental study protocol. - Concurrent anticancer treatment with any agent other than iniparib and any co-administered chemotherapeutic agent(s) specified on the parental study protocol are not permitted throughout the course of the study. - Patient is receiving concurrent radiation therapy to treat primary disease with curative intent. (Note that palliative radiotherapy is allowed as long as there is no evidence of progressive disease.) - Patient is unable to comply with the requirements of the study. - Pregnant or breast-feeding women. - Women of childbearing potential or men with partners of childbearing potential who are not protected or who are unwilling to use an effective contraceptive method of birth control during the course of the study and for a period of 6 months following the last dose. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
Belgium | Investigational Site Number 056002 | Leuven | |
Italy | Investigational Site Number 380002 | Genova | |
Spain | Investigational Site Number 724001 | Valencia | |
United States | Investigational Site Number 840010 | Albany | New York |
United States | Investigational Site Number 840063 | Augusta | Georgia |
United States | Investigational Site Number 840007 | Austin | Texas |
United States | Investigational Site Number 840013 | Birmingham | Alabama |
United States | Investigational Site Number 840030 | Boston | Massachusetts |
United States | Investigational Site Number 840015 | Charlotte | North Carolina |
United States | Investigational Site Number 840060 | Cincinnati | Ohio |
United States | Investigational Site Number 840043 | Cleveland | Ohio |
United States | Investigational Site Number 840008 | Denver | Colorado |
United States | Investigational Site Number 840001 | Detroit | Michigan |
United States | Investigational Site Number 840003 | El Paso | Texas |
United States | Investigational Site Number 840012 | Indianapolis | Indiana |
United States | Investigational Site Number 840002 | Jackson | Mississippi |
United States | Investigational Site Number 840027 | Jacksonville | Florida |
United States | Investigational Site Number 840022 | Las Vegas | Nevada |
United States | Investigational Site Number 840039 | Maywood | Illinois |
United States | Investigational Site Number 840028 | Memphis | Tennessee |
United States | Investigational Site Number 840006 | Minneapolis | Minnesota |
United States | Investigational Site Number 840005 | Norfolk | Virginia |
United States | Investigational Site Number 840021 | Pittsburgh | Pennsylvania |
United States | Investigational Site Number 840019 | Plano | Texas |
United States | Investigational Site Number 840004 | Saint Louis | Missouri |
United States | Investigational Site Number 840059 | Saint Louis | Missouri |
United States | Investigational Site Number 840033 | Santa Maria | California |
United States | Investigational Site Number 840025 | Sioux City | Iowa |
United States | Investigational Site Number 840055 | Tucker | Georgia |
United States | Investigational Site Number 840046 | Vallejo | California |
United States | Investigational Site Number 840009 | Vancouver | Washington |
United States | Investigational Site Number 840017 | Voorhees | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
United States, Belgium, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with incidence of adverse events by NCI-CTCAE version 4.03 | Up to 30 days after last treatment dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |